Enrico Picozza Biography and Net Worth

Enrico Picozza is a partner of HLM Venture Partners, a venture firm that invests in tech-enabled healthcare services, healthcare information technology, and medical device and diagnostics companies. He is also currently a director of AbleTo, mPulseMobile, RubiconMD and a board observer to OnShift. His previous board appointments included Vericare (sold to MedOptions), Spinal Kenetics (sold to Orthofix), Transend Medical (sold to Alcon), Medicalis (sold to Siemens), Aventura (sold to Philips), SensAble Technologies (sold to 3D Systems) and was a board observer and special advisor to Interlace Medical (sold to Hologic), and Tandem Diabetes (NASDAQ). Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. Enrico was part of the startup team within Perkin Elmer involved in the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology. Enrico is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. He is the author of numerous scientific papers and has been a frequent international speaker. Enrico attended the University of Connecticut for undergraduate and postgraduate studies in the major Molecular and Cell Biology.